Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Liposarcoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 96 Cholangiocarcinoma 22 Carcinoma, Renal Cell 15 Liver Neoplasms 10 Biliary Tract Neoplasms 8 Stomach Neoplasms 7 Endometrial Neoplasms 7 Breast Neoplasms 7 Thyroid Neoplasms 6 Neoplasms 6 Recurrence 5 Melanoma 4 Uterine Cervical Neoplasms 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Advanced Biliary Tract Cancer 3 Uveal Melanoma 2 Thyroid Carcinoma, Anaplastic 2 Thyroid Cancer, Papillary 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Paraganglioma, Extra-Adrenal 2 Neuroendocrine Tumors 2 Mesothelioma, Malignant 2 Liver Diseases 2 Fallopian Tube Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Medullary 2

Interventions

Doxorubicin 7 Radiotherapy 6 pazopanib 4 Trabectedin 4 Gemcitabine 4 ribociclib 3 palbociclib 3 eribulin 3 selinexor 2 liposomal doxorubicin 2 avelumab 2 Sunitinib 2 Ifosfamide 2 Docetaxel 2 Cyclophosphamide 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 sotigalimab 1 sodium thiosulfate 1 sitravatinib 1 silmitasertib 1 sargramostim 1 romidepsin 1 regorafenib 1 plitidepsin 1 pembrolizumab 1 pegfilgrastim 1 mirdametinib 1 lenvatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡